| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 03/11/2010 | WO2010027005A1 Substituted amine derivative and medicinal composition comprising same as the active ingredient |
| 03/11/2010 | WO2010027002A1 Ring-fused morpholine derivative having pi3k-inhibiting activity |
| 03/11/2010 | WO2010026993A1 Method for improving absorbability of preparation, and preparation having improved absorbability |
| 03/11/2010 | WO2010026766A1 Agent for treating myelofibrosis |
| 03/11/2010 | WO2010026760A1 Compositions wherein bioactive components are stably sealed |
| 03/11/2010 | WO2010026701A1 Osteogenesis promoter comprising [4-(methylthio)phenylthio]methanebisphosphonic acid or pharmaceutically acceptable salt thereof as active ingredient |
| 03/11/2010 | WO2009156099A8 6-substituted isoquinolines and isoquinolinones |
| 03/11/2010 | US20100063260 Whitefly Ecdysone Receptor Antibody |
| 03/11/2010 | US20100063110 Orally administrable films |
| 03/11/2010 | US20100063079 Pyrimidyl Sulphone Amide Derivatives as Chemokine Receptor Modulators |
| 03/11/2010 | US20100063060 Therapeutic agent for glaucoma comprising Rho Kinhase inhibitor and prostaglandin |
| 03/11/2010 | US20100063056 Bipyridine carboxamide orexin receptor antagonists |
| 03/11/2010 | US20100063019 Low Dose Estrogen Interrupted Hormone Replacement Therapy |
| 03/11/2010 | US20100063010 Method for administering a spill resistant pharmaceutical system |
| 03/11/2010 | US20100062994 Adenosine Receptor Antagonists |
| 03/11/2010 | US20100062977 TCR-Independent Activation of T Cells |
| 03/11/2010 | US20100062073 Pharmaceutical compositions comprising nanoparticles comprising enteric polymers casein |
| 03/11/2010 | US20100062072 Method for the delivery of a biologically active agent |
| 03/11/2010 | US20100062067 Compositions comprising macromolecular assemblies of lipid and surfactant |
| 03/11/2010 | US20100062055 Lipid-based nitric oxide donors |
| 03/11/2010 | US20100062054 Lipobeads and their production |
| 03/11/2010 | US20100062034 Membrane shell of an implantable dosage system |
| 03/11/2010 | US20100061985 Antagonists of tweak and of tweak receptor and their use to treat immunological disorders |
| 03/11/2010 | US20100061971 Method for Treating Human Diseases Associated With an Increased Deoxyribonucleic Acid Content in Extracellular Spaces of Tissues and a Medicinal Preparation for Carrying Out Said Method |
| 03/11/2010 | US20100061970 CBLB for Treating Endotoxin-Mediated Disorders |
| 03/11/2010 | US20100061963 Methods of Improving Stem Cell Homing and Engraftment |
| 03/11/2010 | CA2735709A1 Agent for treating myelofibrosis |
| 03/10/2010 | EP2161258A2 4-oxoquinoline compound and use thereof as hiv integrase inhibitor |
| 03/10/2010 | EP2161023A2 Anti-angiogenic agents and methods of use. |
| 03/10/2010 | EP2160470A2 Chimeric pufa polyketide synthase systems and uses thereof |
| 03/10/2010 | EP1511752B3 Camptothecins with a modified lactone ring |
| 03/10/2010 | EP1423376B1 Bicyclic compound, production and use thereof |
| 03/10/2010 | EP1377293B1 Aryl and biaryl piperidines used as mch antagonists |
| 03/10/2010 | EP1313699B1 5-asa derivatives having anti-inflammatory and antibiotic activity and methods of treating diseases therewith |
| 03/10/2010 | EP1114061B1 FACTOR VIIa INHIBITORS |
| 03/10/2010 | EP1023315B1 Methods and compositions for destruction of selected proteins |
| 03/10/2010 | EP0932678B2 A family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof |
| 03/10/2010 | CN101664545A Therapies for renal failure using interferon-beta |
| 03/10/2010 | CN101664388A transnasal transport/immunisation with highly adaptable carriers |
| 03/10/2010 | CN100593401C Combination of an aromatase inhibitor with a bisphosphonate |
| 03/09/2010 | US7674921 cloprostenol or latanoprost; topical use; highly crystalline structures that are easy to formulate into ophthalmic solutions; hydrolysis of these analogs releases only the active PGF2 alpha analog free acid, without the production of toxic and irritant small aliphatic alcohol coproducts |
| 03/09/2010 | US7674887 3'-{N'-[1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acid; thrombocytopenia and megakaryocytopoiesis treatment |
| 03/09/2010 | US7674830 Reducing blood glucose concentrations, weight loss, and treating diseases and conditions mediated by the cyclooxygenase-2 and 5-lipoxygenase enzymes; an enzyme inhibitors |
| 03/09/2010 | US7674825 Cardiovascular disorders; stimulant of guanylate cyclase |
| 03/09/2010 | US7674823 DNA-PK inhibitors |
| 03/09/2010 | US7674809 Anti-inflammatory and analgesic heterocyclic amidines that inhibit nitrogen oxide (NO) production |
| 03/09/2010 | US7674777 Immunostimulatory nucleic acid molecules |
| 03/09/2010 | US7674775 4-(N (S-glutathionylacetyl)amino)phenylarsenoxide (GSAO) and derivatives; antiinflammatory and antitumor agents; blood and autoimmune disorders; viral infections; anticoagulants |
| 03/09/2010 | US7674773 Glycosylated derivative of hypolipemic agents; side effect reduction; therapy for insulin resistance; hyperlipidemia agent; impaired lipid metabolism; lowering cholesterol levels |
| 03/09/2010 | US7674453 Tumor necrosis factor combined with interferon in demyelinating diseases |
| 03/09/2010 | CA2472449C Pharmaceutical composition for oral use with improved absorption |
| 03/09/2010 | CA2431952C Muscarinic antagonists |
| 03/09/2010 | CA2407972C Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptor agonists |
| 03/09/2010 | CA2399813C Indol-3-yl derivatives |
| 03/09/2010 | CA2389476C Treatment of dyskinesia with a h3-histamine receptor agonist |
| 03/09/2010 | CA2342960C G protein-coupled receptor antagonists |
| 03/09/2010 | CA2336702C Sulfonylaminocarboxylic acid n-arylamides as guanylate cyclase activators |
| 03/09/2010 | CA2331726C Modulation of molecular interaction sites on rna and other biomolecules |
| 03/04/2010 | WO2010024405A1 Ifn type-1 production inhibitor and method for searching for same |
| 03/04/2010 | WO2010024396A1 NOVEL EPIGALLOCATECHIN GALLATE TRIMER, AND α-GLUCOSIDASE INHIBITOR COMPRISING EPIGALLOCATECHIN GALLATE POLYMER |
| 03/04/2010 | WO2010024384A1 Anti-hepatitis c virus composition |
| 03/04/2010 | WO2010024356A1 Novel hydroxamic acid derivative having naphthyridine-n-oxide |
| 03/04/2010 | WO2010024298A1 Potassium channel regulator |
| 03/04/2010 | WO2010024262A1 Transfection agent |
| 03/04/2010 | WO2010024258A1 Ring-fused azole derivative having pi3k-inhibiting activity |
| 03/04/2010 | WO2010024227A1 Novel pyrrole derivative having, as substituents, ureide group, aminocarbonyl group and bicyclic group which may have substituent |
| 03/04/2010 | WO2010024204A1 Wrinkle-diminishing agent |
| 03/04/2010 | WO2010024138A1 Glucosyltransferase inhibitor comprising epigallocatechin gallate polymer as active ingredient |
| 03/04/2010 | WO2010024110A1 Oxotetrahydrofuran-2-yl-benzimidazole derivative |
| 03/04/2010 | WO2010023946A1 Novel uracil compound having nitrogenated heterocyclic ring or salt thereof |
| 03/04/2010 | WO2010023917A1 Potentiator of activity of anti-cancer agent and use thereof, and biomarker for prediction of prognosis in cancer patient and use thereof |
| 03/04/2010 | WO2010023725A1 Novel compound signamycin, method for production thereof, and use thereof |
| 03/04/2010 | WO2010022461A1 Sulphated sugars to increase activity of sulphatases en lysosomal storage disorders |
| 03/04/2010 | WO2009151712A3 Substituted phenylcyclohexylglycolates |
| 03/04/2010 | US20100056621 Agonists of a bitter taste receptor and uses thereof |
| 03/04/2010 | US20100056612 Molecular entities for binding, stabilization and cellular delivery of charged molecules |
| 03/04/2010 | US20100056604 Methods for stimulating nervous system regeneration and repair by inhibiting phosphodiesterase type iv |
| 03/04/2010 | US20100056593 Compounds, compositions and methods of using same for modulating uric acid levels |
| 03/04/2010 | US20100056563 Novel 1.8-naphthyridine compounds |
| 03/04/2010 | US20100056521 (aza)indole derivative and use thereof for medical purposes |
| 03/04/2010 | US20100056505 Substituted Pyrazalones |
| 03/04/2010 | US20100056475 Cyclodextrin conjugates |
| 03/04/2010 | US20100056459 Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction Pathway |
| 03/04/2010 | US20100056425 Absorption enhancers such as E.G. BHT, BHA or propyl gallate |
| 03/04/2010 | US20100055789 Method and apparatus for the stimulation of hair growth |
| 03/04/2010 | US20100055744 Dna mini-circles and uses thereof |
| 03/04/2010 | US20100055191 Powder composition, method for producing the same, and food composition, cosmetic composition and pharmaceutical composition containing the same |
| 03/04/2010 | US20100055186 Photocrosslinkable oligo(poly (ethylene glycol) fumarate) hydrogels for cell and drug delivery |
| 03/04/2010 | US20100055176 Method of Treating Fibromyalgia or Associated Functional Symptoms of Fibromyalgia |
| 03/04/2010 | US20100055175 Soft gelatin capsule shells containing oil soluble flavoring and methods of making the same |
| 03/04/2010 | US20100055159 Percutaneous preparations |
| 03/04/2010 | US20100055156 Composition for the topical transmission of active ingredients into the human or animal body |
| 03/04/2010 | US20100055154 Coaxial electrospun fibers and structures and methods of forming the same |
| 03/04/2010 | US20100055122 Chimeric infectious dna clones, chimeric porcine circoviruses and uses thereof |
| 03/04/2010 | US20100055097 Stable lyophilized pharmaceutical formulation of igg antibodies |
| 03/04/2010 | US20100055066 Agent for prophylactic and/or therapeutic treatment of diabetes |
| 03/04/2010 | US20100055038 Methods for Predicting Effectiveness of Apheresis Therapy for Heart Failure |
| 03/04/2010 | DE102008039734A1 Stabilisierung von Zellen durch ionische Flüssigkeiten Stabilization of cells by ionic liquids |
| 03/04/2010 | CA2735419A1 Compound signamycin, method for producing the same, and use of the same |
| 03/04/2010 | CA2734981A1 Oxotetrahydrofuran-2-yl-benzimidazole derivative |